2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Burkitt Lymphoma
Burkitt lymphoma presents a formidable challenge in the realm of cancer research. This rare and aggressive non-Hodgkin lymphoma variant demands keen scientific scrutiny due to its swift proliferation within the lymphatic system, often leading to noticeable swellings in various body regions. Scientists are meticulously probing its genetic and environmental underpinnings, striving to unravel its intricate origins. Breakthroughs in genomic sequencing have unveiled specific genetic aberrations associated with Burkitt lymphoma, paving the path for targeted therapeutic interventions. Immunotherapeutic strategies, including monoclonal antibodies and CAR-T cell therapy, hold significant promise in augmenting treatment efficacy. Moreover, ongoing clinical trials exploring innovative combination therapies and emerging agents aim to revolutionize patient care and survival outcomes. Amidst these endeavors, the quest for deeper insights into Burkitt lymphoma persists, igniting optimism for transformative breakthroughs in its management.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China